{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:38:54Z","timestamp":1771623534282,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.radonc.2023.109576","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:37:13Z","timestamp":1677015433000},"page":"109576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial"],"prefix":"10.1016","volume":"182","author":[{"given":"Reno","family":"Eufemon Cereno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanah","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinn","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ante","family":"Mestrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Carolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siavash","family":"Atrchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Berrang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Valev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilo","family":"Lefresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109576_b0005","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109576_b0010","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0015","doi-asserted-by":"crossref","unstructured":"Harrow S, Palma DA, Olson R, et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol Biol Phys. Published online 2022. doi:10.1016\/j.ijrobp.2022.05.004","DOI":"10.1016\/S0167-8140(22)02480-X"},{"key":"10.1016\/j.radonc.2023.109576_b0020","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(19)30278-8","article-title":"SABR-COMET: harbinger of a new cancer treatment paradigm","volume":"393","author":"Loo","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109576_b0025","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0030","doi-asserted-by":"crossref","unstructured":"Olson RA, Palma DA. Should stereotactic ablative radiotherapy be used for oligometastatic disease? NEJM Evid. 2022;1:EVIDtt2200209. doi:10.1056\/EVIDtt2200209","DOI":"10.1056\/EVIDtt2200209"},{"key":"10.1016\/j.radonc.2023.109576_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.109576_b0040","first-page":"1","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer","volume":"9","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0045","doi-asserted-by":"crossref","unstructured":"Baker S, Jiang W, Mou B, et al. Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial. Int J Radiat Oncol Biol Phys. Published online 2022. doi:10.1016\/j.ijrobp.2022.05.033","DOI":"10.1016\/j.ijrobp.2022.05.033"},{"key":"10.1016\/j.radonc.2023.109576_b0050","doi-asserted-by":"crossref","unstructured":"Baker S, Mou B, Jiang W, et al. Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase 2 SABR-5 Trial. Int J Radiat Oncol Biol Phys. 2022;000. doi:10.1016\/j.ijrobp.2022.06.094.","DOI":"10.1016\/j.ijrobp.2022.06.094"},{"key":"10.1016\/j.radonc.2023.109576_b0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.radonc.2018.05.012","article-title":"Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?","volume":"128","author":"Diamant","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/0284186X.2021.1874617","article-title":"Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? an analysis of the UK\u2019s largest cohort of lung SABR patients","volume":"60","author":"Saha","year":"2021","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.radonc.2023.109576_b0065","doi-asserted-by":"crossref","unstructured":"Palma DA, Haasbeek C, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer. 2012;12:no pagination. https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-305","DOI":"10.1186\/1471-2407-12-305"},{"key":"10.1016\/j.radonc.2023.109576_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.109576_b0075","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150963","article-title":"The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy","volume":"89","author":"Shaverdian","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.109576_b0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0090","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ctrv.2014.09.003","article-title":"Predictors and management of chest wall toxicity after lung stereotactic body radiotherapy","volume":"40","author":"Shaikh","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2023.109576_b0095","doi-asserted-by":"crossref","unstructured":"Duijm M, van der Voort van Zyp NC, Granton P V., et al. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy. Acta Oncol (Madr). 2020;59:809-817. doi:10.1080\/0284186X.2020.1750693","DOI":"10.1080\/0284186X.2020.1750693"},{"key":"10.1016\/j.radonc.2023.109576_b0100","doi-asserted-by":"crossref","unstructured":"an Oirschot M, Bergman A, Verbakel WFAR, et al. Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial. Int J Radiat Oncol Biol Phys. Published online 2022. doi:10.1016\/j.ijrobp.2022.01.002","DOI":"10.1016\/j.ijrobp.2022.01.002"},{"key":"10.1016\/j.radonc.2023.109576_b0105","doi-asserted-by":"crossref","unstructured":"Cereno RE, Bartlett Q, Lamey M, Hyde D, Mou B. Assessment of intrafraction motion for spine and non-spine bone metastases treated with image-guided stereotactic body radiotherapy without 6 degrees-of-freedom couch correction. J Radiosurgery SBRT. Published online 2022","DOI":"10.1016\/S0167-8140(22)04422-X"},{"key":"10.1016\/j.radonc.2023.109576_b0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2020.03.005","article-title":"Correlating dose variables with local tumor control in stereotactic body radiation therapy for early-stage non-small cell lung cancer: a modeling study on 1500 individual treatments","volume":"107","author":"Klement","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109576_b0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease \u2013 influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.radonc.2015.09.008","article-title":"Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy","volume":"118","author":"Guckenberger","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109576_b0125","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.21873\/anticanres.14610","article-title":"Predictors of local control for stereotactic ablative radiotherapy (SAbR) in pulmonary oligometastases from gastrointestinal malignancies","volume":"40","author":"Simoni","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2023.109576_b0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/0284186X.2018.1445285","article-title":"Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy","volume":"57","author":"Sharma","year":"2018","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.radonc.2023.109576_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:43Z","timestamp":1759123543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023001147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0167814023001147"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109576","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109576"}}